MXPA06014771A - Perfiles de antigeno asociados a tumor en diagnosticos de cancer e inmunoterapia. - Google Patents

Perfiles de antigeno asociados a tumor en diagnosticos de cancer e inmunoterapia.

Info

Publication number
MXPA06014771A
MXPA06014771A MXPA06014771A MXPA06014771A MXPA06014771A MX PA06014771 A MXPA06014771 A MX PA06014771A MX PA06014771 A MXPA06014771 A MX PA06014771A MX PA06014771 A MXPA06014771 A MX PA06014771A MX PA06014771 A MXPA06014771 A MX PA06014771A
Authority
MX
Mexico
Prior art keywords
tumor
antigen
cancer
tuaas
protein
Prior art date
Application number
MXPA06014771A
Other languages
English (en)
Spanish (es)
Inventor
Chih-Sheng Chiang
John J L Simard
Original Assignee
Mannkind Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35478743&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MXPA06014771(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Mannkind Corp filed Critical Mannkind Corp
Publication of MXPA06014771A publication Critical patent/MXPA06014771A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MXPA06014771A 2004-06-17 2005-06-17 Perfiles de antigeno asociados a tumor en diagnosticos de cancer e inmunoterapia. MXPA06014771A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58096904P 2004-06-17 2004-06-17
PCT/US2005/021836 WO2006002114A2 (en) 2004-06-17 2005-06-17 Tumor-associated antigen profiles in cancer diagnostics and immunotherapy

Publications (1)

Publication Number Publication Date
MXPA06014771A true MXPA06014771A (es) 2007-03-21

Family

ID=35478743

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA06014771A MXPA06014771A (es) 2004-06-17 2005-06-17 Perfiles de antigeno asociados a tumor en diagnosticos de cancer e inmunoterapia.

Country Status (10)

Country Link
EP (1) EP1782070B1 (https=)
JP (1) JP2008503498A (https=)
AT (1) ATE480776T1 (https=)
AU (1) AU2005258014B2 (https=)
CA (1) CA2571070A1 (https=)
DE (1) DE602005023488D1 (https=)
DK (1) DK1782070T3 (https=)
ES (1) ES2351995T3 (https=)
MX (1) MXPA06014771A (https=)
WO (1) WO2006002114A2 (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7498298B2 (en) 2003-11-06 2009-03-03 Seattle Genetics, Inc. Monomethylvaline compounds capable of conjugation to ligands
US20060008468A1 (en) * 2004-06-17 2006-01-12 Chih-Sheng Chiang Combinations of tumor-associated antigens in diagnostics for various types of cancers
AU2005321898B2 (en) * 2004-12-29 2012-07-19 Mannkind Corporation Use of compositions comprising various tumor-associated antigens as anti-cancer vaccines
EP2032719A2 (en) * 2006-06-02 2009-03-11 GlaxoSmithKline Biologicals S.A. Method for identifying whether a patient will be responder or not to immunotherapy
NZ583318A (en) 2007-07-16 2012-07-27 Genentech Inc Humanized anti-cd79b antibodies and immunoconjugates and methods of use
DK2474557T3 (da) 2007-07-16 2014-11-10 Genentech Inc Anti-CD79b-antistoffer og immunkonjugater og fremgangsmåder til anvendelse
GB0720118D0 (en) * 2007-10-15 2007-11-28 Achour Adnane Modified mhc class 1 binding peptides
WO2009068621A1 (en) * 2007-11-30 2009-06-04 Glaxosmithkline Biologicals S.A. Method for classifying cancer patients as responder or non-responder to immunotherapy
SG187517A1 (en) 2008-01-31 2013-02-28 Genentech Inc Anti-cd79b antibodies and immunoconjugates and methods of use
AU2009215503B2 (en) * 2008-02-20 2014-05-08 Arizona Cancer Therapeutics, Llc Use of therapeutic peptides for the treatment and prevention of cancer
GB0822836D0 (en) * 2008-12-15 2009-01-21 Oxford Biomedica Ltd Method
US20120100538A1 (en) 2009-03-24 2012-04-26 Biocept, Inc. Devices and methods of cell capture and analysis
AU2010229924B2 (en) 2009-03-24 2016-07-21 Plus Therapeutics Inc. Devices and methods of cell capture and analysis
JP2013544237A (ja) 2010-10-12 2013-12-12 アリゾナ バイオメディカル リサーチ コミッション Ｅｇｆｒベースのペプチド
US10066004B2 (en) 2010-10-12 2018-09-04 Arizona Cancer Therapeutics, Llc EGFR-based inhibitor peptides for combinatorial inactivation of ERBB1, ERBB2, and ERBB3
PE20141114A1 (es) 2010-12-20 2014-09-15 Genentech Inc Anticuerpos anti-mesotelina e inmunoconjugados
US20150044224A1 (en) * 2012-03-02 2015-02-12 H. Lee Moffitt Cancer Center And Research Institute, Inc. Materials and methods for differential treatment of cancer
WO2014074785A1 (en) * 2012-11-08 2014-05-15 Ludwig Institute For Cancer Research Ltd. Methods of predicting outcome and treating breast cancer
PT3262071T (pt) 2014-09-23 2020-06-16 H Hoffnabb La Roche Ag Métodos de utilização de imunoconjugados anti-cd79b
JP2019505512A (ja) 2016-01-08 2019-02-28 バッシボディ アクスイェ セルスカプ 治療用抗癌ネオエピトープワクチン
WO2017176946A1 (en) * 2016-04-05 2017-10-12 The Board Of Trustees Of The Leland Stanford Junior University Systems and methods for targeted therapy based on single-cell stimulus perturbation response
WO2020150513A1 (en) * 2019-01-17 2020-07-23 Fred Hutchinson Cancer Research Center Methods to enhance the selectivity and effectiveness of cancer treatments
US20220370586A1 (en) * 2019-08-08 2022-11-24 Cedars-Sinai Medical Center Method of generating activated t cells for cancer therapy

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4940670A (en) * 1986-01-24 1990-07-10 Rhodes Buck A Method for compounding and testing patient specific monoclonal antibodies and monoclonal antibody fragments for in vivo use
US6794501B2 (en) 2001-05-04 2004-09-21 Ludwig Institute For Cancer Research Colon cancer antigen panel
DE10225139A1 (de) * 2002-05-29 2004-02-26 Immatics Biotechnologies Gmbh Verfahren zur Identifizierung von immunreaktiven Peptiden

Also Published As

Publication number Publication date
AU2005258014B2 (en) 2012-07-12
EP1782070A2 (en) 2007-05-09
WO2006002114A2 (en) 2006-01-05
ATE480776T1 (de) 2010-09-15
WO2006002114A3 (en) 2006-10-05
ES2351995T3 (es) 2011-02-14
JP2008503498A (ja) 2008-02-07
DK1782070T3 (da) 2011-01-03
AU2005258014A1 (en) 2006-01-05
DE602005023488D1 (de) 2010-10-21
EP1782070B1 (en) 2010-09-08
CA2571070A1 (en) 2006-01-05

Similar Documents

Publication Publication Date Title
US20120258462A1 (en) Combinations of tumor-associated antigens in diagnostics for various types of cancers
AU2005258014B2 (en) Tumor-associated antigen profiles in cancer diagnostics and immunotherapy
JP5283335B2 (ja) 各種癌の治療を目的とした腫瘍関連抗原の組合せ
AU2005321898B2 (en) Use of compositions comprising various tumor-associated antigens as anti-cancer vaccines
US20060159689A1 (en) Combinations of tumor-associated antigens in diagnostics for various types of cancers
JP6513086B2 (ja) 癌治療法の決定のための腫瘍抗原
US10429392B2 (en) Methods and compositions for diagnosis and treatment of cancer
Reynolds et al. Stimulation of CD8+ T cell responses to MAGE‐3 and Melan A/MART‐1 by immunization to a polyvalent melanoma vaccine
Duperret et al. A designer cross-reactive DNA immunotherapeutic vaccine that targets multiple MAGE-A family members simultaneously for cancer therapy
US20110274723A1 (en) Cancer immunotherapy and method of treatment
JP2003502273A (ja) 正常な前立腺、精巣、および子宮ならびに新生物性の前立腺、精巣、および子宮に発現されたｘ連鎖ｇａｇｅ様遺伝子であるｐａｇｅ−４、ならびにその使用
JP2003500072A (ja) 癌関連薬剤およびその使用

Legal Events

Date Code Title Description
FG Grant or registration